321
Views
7
CrossRef citations to date
0
Altmetric
Research Article

Intratympanic steroids for combined treatment of idiopathic sudden hearing loss: when is it too late?

, , &
Pages 632-635 | Received 26 Mar 2019, Accepted 28 Apr 2019, Published online: 24 May 2019
 

Abstract

Background: Idiopathic sudden sensorineural hearing loss (ISSNHL) requires early treatment.

Objective: To describe our experience on intratympanic steroid treatment (ITS) of ISSNHL analyzing the delay to start therapy as prognostic factor.

Material and methods: We perform a retrospective study on ISSNHL treated with systemic steroids without full recovery on PTA (pure tone average) according to Siegel criteria. They were divided into two different groups: one group that additionally received ITS as combined therapy (treatment group), and another without it (control group). We analyzed the hearing recovery at 6 months and 2 years, and the influence of the delay to start ITS in the recovery.

Results: After ITS was added, further complete recovery was achieved in 10 patients of the treatment group. After 6 months, PTA improvement in the treatment group was 10.84 dB, compared to 1.13 dB in the control group (p<.0001). Nevertheless, patients starting such combination of oral steroids and ITS within 8 days of diagnosis had an additional gain of 15 dB in the first 6 months, that increased to 19.17 dB after 24 months (p<.022).

Conclusions: When ITS was added within the first 8 days, a significantly better and more stable response was obtained.

Chinese abstract

背景:特发性突发性感觉神经性听力损失(ISSNHL)需要早期治疗。

目的:描述ISSNHL鼓室内类固醇治疗(ITS)的经验, 将延迟开始治疗作为预后因素进行分析。

材料和方法:我们回顾性研究了全身类固醇治疗ISSNHL, 但根据西格尔标准, 未完全恢复PTA(纯音平均值)。研究对象被分为两组:一组额外接受ITS联合治疗(治疗组), 另一组不接受联合治疗(对照组)。我们分析了6个月和2年的听力恢复情况, 以及延迟开始ITS治疗对听力恢复的影响。

结果:增加ITS治疗后, 治疗组10例患者均获得完全康复。6个月后, 治疗组的PTA改善率为10.84 dB, 而对照组为1.13 dB(p < 0.0001)。然而, 在确诊后8天内开始口服类固醇和ITS联合治疗的患者在前6个月内额外提高15 dB, 24个月后提高到19.17 dB(p < 0.022)。

结论:在前8天内加入ITS治疗, 可获得较好、稳定的疗效。

Disclosure statement

No potential conflict of interest was reported by the authors.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.